Solventum (NYSE:SOLV) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Solventum (NYSE:SOLV) had its price objective raised by research analysts at Morgan Stanley from $60.00 to $73.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 3.26% from the company’s current price.

Other equities research analysts have also issued reports about the stock. Wolfe Research began coverage on shares of Solventum in a research note on Thursday, September 26th. They set a “peer perform” rating on the stock. BTIG Research began coverage on shares of Solventum in a research note on Thursday, September 5th. They set a “neutral” rating on the stock. Piper Sandler increased their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research note on Friday, November 8th. Wells Fargo & Company lowered their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research note on Friday, August 9th. Finally, The Goldman Sachs Group increased their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $68.00.

Solventum Price Performance

NYSE:SOLV opened at $70.70 on Monday. The firm’s fifty day moving average is $70.23 and its two-hundred day moving average is $62.07. The company has a quick ratio of 0.96, a current ratio of 1.31 and a debt-to-equity ratio of 2.90. Solventum has a one year low of $47.16 and a one year high of $96.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of SOLV. Daiwa Securities Group Inc. raised its holdings in Solventum by 12.2% in the 3rd quarter. Daiwa Securities Group Inc. now owns 17,623 shares of the company’s stock valued at $1,229,000 after acquiring an additional 1,919 shares during the last quarter. Centaurus Financial Inc. acquired a new stake in Solventum in the 3rd quarter valued at about $321,000. Swedbank AB raised its holdings in Solventum by 20.3% in the 3rd quarter. Swedbank AB now owns 107,197 shares of the company’s stock valued at $7,474,000 after acquiring an additional 18,108 shares during the last quarter. KKM Financial LLC raised its holdings in Solventum by 7.9% in the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock valued at $304,000 after acquiring an additional 319 shares during the last quarter. Finally, Cerity Partners LLC raised its holdings in Solventum by 27.4% in the 3rd quarter. Cerity Partners LLC now owns 52,719 shares of the company’s stock valued at $3,676,000 after acquiring an additional 11,337 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.